Recombinant Anti-Thyroglobulin antibody [EPR9730(IHC)] - BSA and Azide free (ab249444)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9730(IHC)] to Thyroglobulin - BSA and Azide free
- Suitable for: IHC-P, ICC/IF
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Thyroglobulin antibody [EPR9730(IHC)] - BSA and Azide free
See all Thyroglobulin primary antibodies -
Description
Rabbit monoclonal [EPR9730(IHC)] to Thyroglobulin - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, ICC/IFmore details
Unsuitable for: IP or WB -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Recombinant full length protein corresponding to Human Thyroglobulin aa 1-2800.
Database link: P01266 -
General notes
ab249444 is the carrier-free version of ab168344.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR9730(IHC) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab249444 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
Notes |
---|
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
Use at an assay dependent concentration. |
Target
-
Function
Precursor of the iodinated thyroid hormones thyroxine (T4) and triiodothyronine (T3). -
Tissue specificity
Thyroid gland specific. -
Involvement in disease
Defects in TG are the cause of congenital hypothyroidism due to dyshormonogenesis type 3 (CHDH3) [MIM:274700]. A disorder due to thyroid dyshormonogenesis, causing large goiters of elastic and soft consistency in the majority of patients. Although the degree of thyroid dysfunction varies considerably among patients with defective thyroglobulin synthesis, patients usually have a relatively high serum free triiodothyronine (T3) concentration with disproportionately low free tetraiodothyronine (T4) level. The maintenance of relatively high free T3 levels prevents profound tissue hypothyroidism except in brain and pituitary, which are dependent on T4 supply, resulting in neurologic and intellectual defects in some cases.
Variations in TG are associated with susceptibility to autoimmune thyroid disease type 3 (AITD3) [MIM:608175]. AITDs including Graves disease (GD) and Hashimoto thyroiditis (HT), are among the most common human autoimmune diseases. They are complex diseases, which are caused by an interaction between susceptibility genes and nongenetic factors, such as infection. -
Sequence similarities
Belongs to the type-B carboxylesterase/lipase family.
Contains 11 thyroglobulin type-1 domains. -
Post-translational
modificationsSulfated tyrosines are desulfated during iodination. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 7038 Human
- Omim: 188450 Human
- SwissProt: P01266 Human
- Unigene: 654591 Human
-
Alternative names
- AITD 3 antibody
- AITD3 antibody
- hTG antibody
see all
Images
-
This data was developed using ab168344, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human thyroid gland papillary carcinoma tissue labelingThyroglobulin with ab168344 at 1/250 dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. -
This data was developed using ab168344, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human thyroid gland follicular carcinoma tissue labeling Thyroglobulin with ab168344 at 1/250 dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab249444 has not yet been referenced specifically in any publications.